Trial Outcomes & Findings for Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children (NCT NCT03159104)
NCT ID: NCT03159104
Last Updated: 2023-08-21
Results Overview
The total scholastic skill score is calculated based on the points for reading, spelling, and counting skills. Reading skills are estimated according to scale consisting of three subscales:reading speed, reading method/understanding, and reading accuracy. The minimum value of reading skills scale is 0 points, and the maximum value is 45 points. Spelling skills are estimated according to scale in 0, 15, 30, and 45 points. The minimum value is 0 points, and the maximum value is 45 points. Counting skills are estimated according to subtest No. 3 "Arithmetic" of "Wechsler Intelligence Scale for Children" (WISC) in points. The minimum value is 0 points, and the maximum value is 20 points. Total scholastic skill score is a sum of three scales (reading, spelling, and counting). The minimum value is 0 points, and the maximum value is 110 points. A higher score means the best results.
COMPLETED
PHASE3
240 participants
On Day 1 and after 12 weeks of the therapy
2023-08-21
Participant Flow
Participant milestones
| Measure |
Tenoten for Children
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Tenoten for children: Tablet for oral use.
|
Placebo
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Placebo: Tablet for oral use.
|
|---|---|---|
|
Overall Study
STARTED
|
122
|
118
|
|
Overall Study
COMPLETED
|
121
|
116
|
|
Overall Study
NOT COMPLETED
|
1
|
2
|
Reasons for withdrawal
| Measure |
Tenoten for Children
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Tenoten for children: Tablet for oral use.
|
Placebo
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Placebo: Tablet for oral use.
|
|---|---|---|
|
Overall Study
Violation of inclusion criteria
|
1
|
2
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Tenoten for children: Tablet for oral use.
|
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Placebo: Tablet for oral use.
|
Total
n=237 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
121 Participants
n=121 Participants
|
116 Participants
n=116 Participants
|
237 Participants
n=237 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
0 Participants
n=121 Participants
|
0 Participants
n=116 Participants
|
0 Participants
n=237 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=121 Participants
|
0 Participants
n=116 Participants
|
0 Participants
n=237 Participants
|
|
Age, Continuous
|
8.5 years
STANDARD_DEVIATION 0.7 • n=121 Participants
|
8.6 years
STANDARD_DEVIATION 0.6 • n=116 Participants
|
8.6 years
STANDARD_DEVIATION 0.7 • n=237 Participants
|
|
Sex: Female, Male
Female
|
49 Participants
n=121 Participants
|
46 Participants
n=116 Participants
|
95 Participants
n=237 Participants
|
|
Sex: Female, Male
Male
|
72 Participants
n=121 Participants
|
70 Participants
n=116 Participants
|
142 Participants
n=237 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Region of Enrollment
Russia
|
121 participants
n=121 Participants
|
116 participants
n=116 Participants
|
237 participants
n=237 Participants
|
PRIMARY outcome
Timeframe: On Day 1 and after 12 weeks of the therapyThe total scholastic skill score is calculated based on the points for reading, spelling, and counting skills. Reading skills are estimated according to scale consisting of three subscales:reading speed, reading method/understanding, and reading accuracy. The minimum value of reading skills scale is 0 points, and the maximum value is 45 points. Spelling skills are estimated according to scale in 0, 15, 30, and 45 points. The minimum value is 0 points, and the maximum value is 45 points. Counting skills are estimated according to subtest No. 3 "Arithmetic" of "Wechsler Intelligence Scale for Children" (WISC) in points. The minimum value is 0 points, and the maximum value is 20 points. Total scholastic skill score is a sum of three scales (reading, spelling, and counting). The minimum value is 0 points, and the maximum value is 110 points. A higher score means the best results.
Outcome measures
| Measure |
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Tenoten for children: Tablet for oral use.
|
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Placebo: Tablet for oral use.
|
|---|---|---|
|
Mean Total Scholastic Skills Score (a Sum of Three Scales: Reading, Spelling, and Counting).
Baseline
|
61.39 score on a scale
Standard Deviation 12.04
|
60.46 score on a scale
Standard Deviation 11.04
|
|
Mean Total Scholastic Skills Score (a Sum of Three Scales: Reading, Spelling, and Counting).
After 12 weeks
|
79.94 score on a scale
Standard Deviation 18.22
|
74.56 score on a scale
Standard Deviation 18.75
|
SECONDARY outcome
Timeframe: On Day 1 and after 12 weeks of the therapyReading skills are estimated according to scale consisting of three subscales: reading speed, reading method/understanding, and reading accuracy. Students of 7 years old are invited to read the words, and students of 8-9 years old are invited to read a small text. Speed, method, and accuracy of the reading are estimated in students of 7 years old. Speed, accuracy, and understanding of the text are estimated in students of 8-9 years old. The minimum value is 0 points, and the maximum value is 45 points. A higher score meant the best results.
Outcome measures
| Measure |
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Tenoten for children: Tablet for oral use.
|
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Placebo: Tablet for oral use.
|
|---|---|---|
|
Mean Reading Skills Score
Baseline
|
27.69 score on a scale
Standard Deviation 6.52
|
27.76 score on a scale
Standard Deviation 6.16
|
|
Mean Reading Skills Score
After 12 weeks
|
34.96 score on a scale
Standard Deviation 6.66
|
33.66 score on a scale
Standard Deviation 7.7
|
SECONDARY outcome
Timeframe: On Day 1 and after 12 weeks of the therapySpelling skills are estimated according to scale in 0, 15, 30, and 45 points. Students of 7 years old are invited to write dictated letters, their names, and three words (mom, table, trunk), and students of 8-9 years old are invited to write a small dictation. Dysgraphic errors and their types as well as the number of non-dysgraphic errors are taken into consideration for estimation. The minimum value is 0 points, and the maximum value is 45 points. A higher score meant the best results.
Outcome measures
| Measure |
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Tenoten for children: Tablet for oral use.
|
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Placebo: Tablet for oral use.
|
|---|---|---|
|
Mean Score Spelling Skills Score
Baseline
|
22.56 score on a scale
Standard Deviation 7.53
|
21.59 score on a scale
Standard Deviation 7.48
|
|
Mean Score Spelling Skills Score
After 12 weeks
|
32.73 score on a scale
Standard Deviation 13.69
|
29.09 score on a scale
Standard Deviation 14.58
|
SECONDARY outcome
Timeframe: On Day 1 and after 12 weeks of the therapyCounting skills are estimated according to subtest No. 3 "Arithmetic" of "Wechsler Intelligence Scale for Children" (WISC) in points. "Arithmetic" subtest includes 16 tasks from elementary school arithmetic which are tackled verbally. Easiness of operating numbers, accuracy, and time spent on the tasks are estimated. Each task is rated in points (0 or 1), by the end of testing and rating for each task the sum of points (raw score) is calculated and converted into a scale score using standard tables. The minimum value is 0 points, and the maximum value is 20 points. A higher score meant the best results.
Outcome measures
| Measure |
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Tenoten for children: Tablet for oral use.
|
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Placebo: Tablet for oral use.
|
|---|---|---|
|
Mean Counting Skills Score.
Baseline
|
11.14 score on a scale
Standard Deviation 2.24
|
11.10 score on a scale
Standard Deviation 2.27
|
|
Mean Counting Skills Score.
After 12 weeks
|
12.26 score on a scale
Standard Deviation 2.80
|
11.80 score on a scale
Standard Deviation 2.73
|
SECONDARY outcome
Timeframe: On Day 1 and after 12 weeks of the therapyPercentage of children with an increase in total scholastic skills score (a sum of three scales: reading, spelling, and counting). Total scholastic skill score is a sum of three scales (reading, spelling, and counting). The minimum value is 0 points, and the maximum value is 110 points. A higher score meant the best results. The increase in total scholastic skills score means an increasing by at least 5 points compared to baseline.
Outcome measures
| Measure |
Tenoten for Children
n=121 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Tenoten for children: Tablet for oral use.
|
Placebo
n=116 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Placebo: Tablet for oral use.
|
|---|---|---|
|
Percentage of Children With an Increase in Total Scholastic Skills Score (a Sum of Three Scales: Reading, Spelling, and Counting).
|
103 Participants
|
80 Participants
|
SECONDARY outcome
Timeframe: In 12 weeks of the treatment.Population: The number of patients who have data on the CGI-EI scale is indicated.
The Clinical Global Impression-Efficiency Index (CGI-E) scale consists of two subscales. Efficacy subscale measures efficacy of medicine based on the severity of symptoms at the end of therapy. The minimum value is 1 points, and the maximum value is 4 points. A higher score means the best results. Side effects subscale measures side effects of the medicine. The minimum value is 1 points, and the maximum value is 4 points. A higher score means the best results. The scale is filled in by the doctor at the final visit after 12 weeks of the treatment. In accordance with the results of treatment, the doctor expresses his opinion about the efficacy of the therapy and the degree of medicine safety, making marks in the appropriate columns of the table. The efficacy index is determined as intersection of columns of indicators of efficacy and side effects in the table. The minimum value is 0.25 points, and the maximum value is 4 points. A higher score means the best results.
Outcome measures
| Measure |
Tenoten for Children
n=118 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Tenoten for children: Tablet for oral use.
|
Placebo
n=112 Participants
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Placebo: Tablet for oral use.
|
|---|---|---|
|
Efficacy Index According to Clinical Global Impression Scale.
|
2.36 score on a scale
Standard Deviation 0.87
|
1.98 score on a scale
Standard Deviation 0.83
|
Adverse Events
Tenoten for Children
Placebo
Serious adverse events
| Measure |
Tenoten for Children
n=122 participants at risk
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Tenoten for children: Tablet for oral use.
|
Placebo
n=118 participants at risk
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Placebo: Tablet for oral use.
|
|---|---|---|
|
Infections and infestations
Phlegmonous appendicitis
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Infections and infestations
Bacterial pneumonia
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
Other adverse events
| Measure |
Tenoten for Children
n=122 participants at risk
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Tenoten for children: Tablet for oral use.
|
Placebo
n=118 participants at risk
Dose per administration: 1 tablet. 1 tablet three times daily (3 tablets per day). The tablets should be held in the mouth until complete dissolution, without meal.
Placebo: Tablet for oral use.
|
|---|---|---|
|
Ear and labyrinth disorders
Hearing loss
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Eye disorders
Eye pain
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Gastrointestinal disorders
Functional indigestion
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Gastrointestinal disorders
Abdominal pain
|
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
|
4.2%
5/118 • Number of events 5 • During the treatment period - 12 weeks.
|
|
Gastrointestinal disorders
Diarrhea
|
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
|
3.4%
4/118 • Number of events 4 • During the treatment period - 12 weeks.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Gastrointestinal disorders
Food intoxication
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Gastrointestinal disorders
Nausea
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Gastrointestinal disorders
Stomatitis
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
1.7%
2/118 • Number of events 2 • During the treatment period - 12 weeks.
|
|
General disorders
Hyperthermia
|
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Immune system disorders
Pseudoallergy
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Infections and infestations
Gastroenteritis
|
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Infections and infestations
Gingivitis
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Infections and infestations
Laryngitis
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Infections and infestations
Nasopharyngitis
|
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
|
4.2%
5/118 • Number of events 5 • During the treatment period - 12 weeks.
|
|
Infections and infestations
Herpes labial
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
1.7%
2/118 • Number of events 2 • During the treatment period - 12 weeks.
|
|
Infections and infestations
Pharyngitis
|
2.5%
3/122 • Number of events 3 • During the treatment period - 12 weeks.
|
1.7%
2/118 • Number of events 2 • During the treatment period - 12 weeks.
|
|
Infections and infestations
ARI
|
5.7%
7/122 • Number of events 7 • During the treatment period - 12 weeks.
|
3.4%
4/118 • Number of events 4 • During the treatment period - 12 weeks.
|
|
Infections and infestations
ARVI
|
11.5%
14/122 • Number of events 14 • During the treatment period - 12 weeks.
|
5.1%
6/118 • Number of events 6 • During the treatment period - 12 weeks.
|
|
Infections and infestations
Rhinitis
|
3.3%
4/122 • Number of events 4 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Infections and infestations
Runny nose
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Infections and infestations
Sinusitis
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Infections and infestations
Tonsillitis
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Nervous system disorders
Headache
|
3.3%
4/122 • Number of events 4 • During the treatment period - 12 weeks.
|
4.2%
5/118 • Number of events 5 • During the treatment period - 12 weeks.
|
|
Nervous system disorders
Hyperactivity
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Nervous system disorders
Tremor
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Psychiatric disorders
Hyperexcitability syndrome
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Psychiatric disorders
Enuresis
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Psychiatric disorders
Insomnia
|
1.6%
2/122 • Number of events 2 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Psychiatric disorders
Obsessions
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Psychiatric disorders
Simple vocal tics
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchial asthma
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
1.7%
2/118 • Number of events 2 • During the treatment period - 12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Nose bleed
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
2.5%
3/118 • Number of events 3 • During the treatment period - 12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Runny nose
|
0.82%
1/122 • Number of events 1 • During the treatment period - 12 weeks.
|
0.00%
0/118 • During the treatment period - 12 weeks.
|
|
Respiratory, thoracic and mediastinal disorders
Vasomotor rhinitis
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Skin and subcutaneous tissue disorders
Allergic dermatitis
|
4.1%
5/122 • Number of events 5 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
|
Skin and subcutaneous tissue disorders
Pitiriasis pink
|
0.00%
0/122 • During the treatment period - 12 weeks.
|
0.85%
1/118 • Number of events 1 • During the treatment period - 12 weeks.
|
Additional Information
Mikhail Putilovskiy, MD, PhD, Clinical and Medical Department Director
MATERIA MEDICA HOLDING
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: OTHER